Navigation Links
Key to out-of-control immune response in lung injury found
Date:8/16/2007

Researchers at the University of Illinois at Chicago College of Medicine have discovered how a protein modulates the inflammatory response in sudden, life-threatening lung failure. The protein's previously unknown role is reported in the August issue of Nature Medicine.

Acute Respiratory Distress Syndrome, or ARDS, is an often fatal complication of severe traumatic injury, bacterial infections, blood transfusions and overdoses of some medications. In ARDS, the lungs become swollen with fluid and breathing becomes impossible. Thirty percent to 40 percent of patients die. There is no effective treatment.

Sepsis, an overwhelming bacterial infection of the blood and organs, is the most common cause of ARDS. When the immune system responds to the infection, molecules called inflammatory cytokines and chemokines are released. These molecules attract inflammatory white blood cells and destroy bacteria, but also lead to fever, swelling and other symptoms of shock and can wreak havoc on the patient in the course of fighting off the infection.

"Without an inflammatory response, bacterial invaders in the lungs can kill, but too intense a response can also be fatal," said Kurt Bachmaier, UIC research assistant professor in pharmacology and first author of the study. "We need a better understanding of how the immune system modulates this defense so that we can understand what goes wrong in life-threatening lung failure."

The researchers created a mouse model that lacks the gene for a protein, called Cblb, which was known to play a crucial role in chronic inflammation and auto-immunity through regulation of T- and B-cells.

When sepsis was induced in mice with and without the Cblb gene, there was a marked difference in the level of the inflammatory response and survival. Mice lacking the Cblb gene were much less likely to survive than control mice.

The UIC researchers were able to show how Cblb regulates the immune response. They showed that in normal mice, a receptor found in lung tissue that induces the release of inflammatory cytokines and chemokines disappears from the cell surface after about an hour, ending the signaling of the immune response.

In the Cblb-deficient mice the receptor stays on the surface, and the inflammatory response is not turned off.

The researchers were also able to show that a protein that controls the production of inflammatory cytokines, called NF-kB, is induced in lung tissue after sepsis by that receptor to a much greater extent from the Cblb-deficient mice than in normal mice. NF-kB is known to induce swelling of tissues.

"There are already early-stage drug trials of treatments for ARDS targeting NF-kB," said Bachmaier. "This discovery has real clinical implications in the treatment and prevention of life-threatening lung failure."

Cblb is a potential drug target that may lead to a new class of anti-bacterial drugs, says Dr. Asrar Malik, distinguished professor and head of pharmacology and a senior author on the paper. Malik and Bachmaier have recently filed a patent on the basis of these findings.


'/>"/>

Contact: Jeanne Galatzer-Levy
jgala@uic.edu
312-996-1583
University of Illinois at Chicago
Source:Eurekalert

Related biology news :

1. Fox Chase Cancer Center scientists identify immune-system mutation
2. NYU Study Reveals How Brains Immune System Fights Viral Encephalitis
3. Genetically modified natural killer immune cells attack, kill leukemia cells
4. Studies reveal methods viruses use to sidestep immune system
5. Jumping gene helps explain immune systems abilities
6. Scientists solve structure of key protein in innate immune response
7. Rats infected as newborns grew up vulnerable to memory problems during an immune challenge
8. NYU study reveals how brains immune system fights viral encephalitis
9. Chemists identify immune system mechanism for methamphetamine binges
10. Multi-purpose protein regulates new protein synthesis and immune cell development
11. Genetically Modified Natural Killer Immune Cells Attack, Kill Leukemia Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/5/2020)... ... June 04, 2020 , ... Murrieta Genomics has ... patent application for simplified sample preparation for Next Generation Genomic Sequencing (NGS) . ... cost, time, and complexity of sample preparation. , “I have been at the bench ...
(Date:5/30/2020)... JOSE, Calif. (PRWEB) , ... May 29, 2020 ... ... and enabler of digital transformation for enterprises globally, has collaborated with EchoNous Inc. ... the FDA. It can measure systolic heart function, which has been clinically ...
(Date:5/28/2020)... and FORT WORTH, Texas (PRWEB) , ... May ... ... stage biopharmaceutical company, announced today that interim results from their 1801 Phase 1/2 ... of Clinical Oncology (ASCO) Annual Meeting which will take place virtually on May ...
Breaking Biology News(10 mins):
(Date:6/23/2020)... ... June 22, 2020 , ... Dracen Pharmaceuticals Inc., ... presented June 22-24 during the American Association for Cancer Research Virtual meeting. One ... the potent, consistent single agent activity in KEAP1 mutant tumor models of NSCLC. ...
(Date:6/19/2020)... ... June 18, 2020 , ... The Vitaspace project was founded ... forces to radically prolong life and find a way (medicine or technology) that will ... was supported by various scientists from all over the world, doctors, and all people ...
(Date:6/11/2020)... ... 2020 , ... PathSensors Inc., a Baltimore biotechnology company, announced ... program funded by the National Institute of Food and Agriculture (NIFA) entitled “Food ... goal was to engineer and develop a field-deployable instrument for portable pathogen and ...
(Date:6/11/2020)... (PRWEB) , ... June 09, 2020 , ... Reducing carbon ... the world. From the Paris Agreement to stock market dips, ways to reduce CO2 ... adding biofuels to their portfolio. Most of the biofuels being produced today are created ...
Breaking Biology Technology: